


SUPPLEMENTARY DATA

Supplementary Figure S1. Analysed populations from ACCORD cohort

Abbreviations: ACCORD, Action to Control Cardiovascular Risk in Diabetes, ACCORDION, Action to Control Cardiovascular Risk in Diabetes post-trial, UACR, urine albumin-creatinine ratio, eGFR, estimated glomerular filtration rate, ESKD, end-stage kidney disease



SUPPLEMENTARY DATA

Supplementary Table S1. Characteristics of study participants by CKD status at the end of ACCORD and ACCORDION study

	Overall	No CKD			Albuminuric non-CKD	Albuminuric CKD	Non-albuminuric CKD	p
		eGFR (≥120)	eGFR (90-120)	eGFR (60-90)				
ACCORD study end								
n (%)*	8387 (100)	653 (7.8)	2319 (27.6)	2565 (30.6)	2266 (27)	243 (2.9)	341 (4.1)	
Follow-up duration (yr; median [IQR])	5.0 (4.3, 5.7)	5.1 (4.3, 5.9)	5.0 (4.2, 5.6)	5.05 (4.3, 5.7)	5.0 (4.3, 5.7)	5.0 (4.2, 5.9)	5.2 (4.3, 5.9)	0.0001
Past smoker (n [%])	3793 (45.2)	280 (42.9)	1011 (43.6)	1196 (46.6)	1088 (48)	85 (35)	133 (39)	<0.0001
Never smoked (n [%])	2420 (28.8)	199 (30.5)	669 (28.8)	772 (30.1)	551 (24.3)	94 (38.6)	135 (39.6)	
HbA1c (%; mean [SD])	7.5 (1.0)	7.6 (1.2)	7.6 (1.2)	7.5 (1.1)	7.7 (1.2)	7.4 (1.0)	7.5 (1.0)	<0.0001
HbA1c (mmol/mol; mean [SD])	59.4 (13.1)	59.4 (14.1)	59.7 (13.2)	58.3 (12)	60.6 (14.1)	57.2 (10.8)	58.2 (11.1)	<0.0001
Triglycerides (mg/dl; median [IQR])	133 (94, 194)	129 (92, 190)	126 (88, 189)	130 (92, 188)	143 (100, 208)	140 (103, 198)	142 (105, 205)	<0.0001
Total cholesterol (mg/dl; median [IQR])	156 (135, 184)	155 (135, 188)	157 (136, 184)	154 (133, 181)	157 (134, 187)	156 (134, 179)	158 (139, 182)	0.04
HDL cholesterol (mg/dl; median [IQR])	42 (35, 50)	43 (36, 50)	43 (36, 51)	42 (36, 51)	40 (34, 49)	41 (33, 48)	42 (35, 51)	<0.0001
Systolic BP (mmHg; mean [SD])	128.7 (17.0)	126.8 (15.8)	127.8 (15.9)	128 (15.6)	131.6 (17.8)	136.6 (19.7)	128.4 (17)	<0.0001
Diastolic BP (mmHg; mean [SD])	67.9 (10.2)	69 (9.7)	69.2 (9.6)	67.5 (10.1)	67.3 (10.7)	65.6 (10.6)	65.9 (10.4)	<0.0001
RAAS blockade (n [%])	6389 (76.1)	462 (70.7)	1738 (74.9)	1925 (75)	1810 (79.9)	184 (75.7)	270 (79.2)	<0.0001
UACR (mg/mmol; median [IQR])	1.4 (0.67, 5.6)	1.1 (0.67, 2.1)	1 (0.56, 1.8)	0.9 (0.56, 2.3)	7.8 (2.2, 27.8)	16.3 (4.1, 64.7)	1.7 (0.9, 4.6)	0.0001
UACR (mg/g; median [IQR])	13 (6, 50)	10 (6, 19)	8 (5, 16)	9 (5, 21)	69 (20, 246)	145 (37, 573)	15 (8, 41)	0.001
eGFR (ml/min/1.73m ² ; median [IQR])	75.7 (59.7, 92.5)	105.3 (88.8, 120.5)	87.7 (74.7, 100)	70 (58.1, 81.1)	71.4 (56, 89.1)	42 (34.4, 49.7)	49.9 (42.2, 58.1)	0.0001
ACCORDION study end								
n (%)*	4910 (100)	401 (8.2)	1450 (31.5)	1545 (29.5)	1203 (24.5)	122 (2.5)	189 (3.8)	
Follow-up duration (yr; median [IQR])	9.6 (8.5, 10.7)	9.8 (8.7, 10.8)	9.5 (8.5, 10.5)	9.7 (8.6, 10.6)	9.4 (8.3, 10.6)	9.3 (7.9, 10.5)	9.7 (8.5, 10.7)	0.0003
HbA1c (%; mean [SD])	7.9 (1.4)	7.9 (1.5)	8.0 (1.5)	7.7 (1.4)	7.9 (1.5)	7.7 (1.2)	7.8 (1.3)	<0.0001
HbA1c (mmol/mol; mean [SD])	62.7 (16.3)	63.1 (17.1)	63.8 (16.9)	61.2 (15.3)	63.4 (17)	60.7 (13.8)	62.5 (14.4)	<0.0001

SUPPLEMENTARY DATA

Triglycerides (mg/dl; median [IQR])	131 (93, 188)	125 (88, 185)	127 (91, 177)	130 (93, 188)	137 (95, 201)	133 (99.5, 193)	148 (96, 206)	<0.0001
HDL cholesterol (mg/dl; median [IQR])	41 (34, 50)	43 (36, 51)	42 (35, 51)	42 (34, 51)	40 (33, 49)	39 (32, 48.5)	41 (34, 51)	0.0001
Systolic BP (mmHg; mean [SD])	132.2 (17.9)	132 (17.1)	130.8 (17.1)	131.9 (17.3)	133.9 (19.4)	137.4 (17.9)	132.2 (18.8)	<0.0001
Diastolic BP (mmHg; mean [SD])	67.9 (10.5)	70 (10.7)	68.7 (10)	67.2 (10.4)	67.6 (10.7)	64.8 (10.5)	66.5 (11)	<0.0001
RAAS blockade (n [%])	3282 (66.8)	254 (63.3)	996 (68.7)	1027 (66.4)	804 (66.8)	70 (57.4)	131 (69.3)	0.07
UACR (mg/mmol; median [IQR])	2.25 (0.9, 10)	1.3 (0.8, 3.6)	1.3 (0.67, 3.2)	1.7 (0.8, 4.9)	12.9 (3.0, 58.6)	18.8 (4.8, 70.4)	3.1 (1.2, 12.3)	0.0001
UACR (mg/g; median [IQR])	20 (8, 109)	12 (7, 32)	12 (6, 29)	15 (7, 44)	115 (27, 519)	167 (43, 623.5)	28 (11, 109)	0.0001
eGFR (ml/min/1.73m ² ; median [IQR])	72.9 (56.2, 90.6)	103 (81, 118.2)	85.1 (69.9, 98.8)	67.2 (55.3, 80)	67.7 (50.1, 85.2)	37.4 (30.1, 48.6)	50.3 (41.8, 57.7)	0.0001

Abbreviations: ACCORD, Action to Control Cardiovascular Risk in Diabetes, ACCORDION, Action to Control Cardiovascular Risk in Diabetes post-trial, CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; yr, year; IQR, interquartile range; HbA1c, glycated hemoglobin; HDL cholesterol, high-density lipoprotein cholesterol; RAAS blockade, renin-angiotensin-aldosterone system blockade; UACR, urine albumin-creatinine ratio.

* Number of people screened for all tests including kidney function, lipids, hba1c and blood pressure etc.